Stargardt Disease clinical trials at University of California Health

4 in progress, 0 open to eligible people

Showing trials for

  • Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

    Sorry, in progress, not accepting new patients

    The purpose of this open-label, multicenter study is to determine the long-term safety, pharmacokinetics and effects of ALK-001 (C20-D3-retinyl acetate) on the progression of Stargardt disease. This study is an extension of NCT02402660 and enrolls participants who are at least 8 years old. Enrollment is by invitation only. Funding Source - FDA OOPD

    at UCLA

  • ALK-001 on Stargardt Disease

    Sorry, accepting new patients by invitation only

    The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD

    at UCLA

  • ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

    Sorry, not currently recruiting here

    This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.

    at UCSF

  • Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with autosomal recessive Stargardt disease 1 (STGD1).

    at UCLA

Our lead scientists for Stargardt Disease research studies include .

Last updated: